File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Atezolizumab Plus Bevacizumab Versus Sorafenib in the Chinese Subpopulation With Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

TitleAtezolizumab Plus Bevacizumab Versus Sorafenib in the Chinese Subpopulation With Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Authors
Qin, SRen, ZFeng, YHYau, TCCWang, BZhao, HBai, YGu, SLi, LHernandez, SXu, DZMulla, SWang, YShuo, HCheng, AL
Issue Date2020
PublisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487
Citation
Liver Cancer (Forthcoming) How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/289769
ISSN
2235-1795
2023 Impact Factor: 11.6
2023 SCImago Journal Rankings: 3.599

 

DC FieldValueLanguage
dc.contributor.authorQin, S-
dc.contributor.authorRen, Z-
dc.contributor.authorFeng, YH-
dc.contributor.authorYau, TCC-
dc.contributor.authorWang, B-
dc.contributor.authorZhao, H-
dc.contributor.authorBai, Y-
dc.contributor.authorGu, S-
dc.contributor.authorLi, L-
dc.contributor.authorHernandez, S-
dc.contributor.authorXu, DZ-
dc.contributor.authorMulla, S-
dc.contributor.authorWang, Y-
dc.contributor.authorShuo, H-
dc.contributor.authorCheng, AL-
dc.date.accessioned2020-10-22T08:17:12Z-
dc.date.available2020-10-22T08:17:12Z-
dc.date.issued2020-
dc.identifier.citationLiver Cancer (Forthcoming)-
dc.identifier.issn2235-1795-
dc.identifier.urihttp://hdl.handle.net/10722/289769-
dc.languageeng-
dc.publisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487-
dc.relation.ispartofLiver Cancer-
dc.rightsLiver Cancer. Copyright © S. Karger AG.-
dc.rightsThis is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g., Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number]. OR This is the un-reviewed and unedited manuscript version of the following article: [insert full citation, e.g., Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].-
dc.titleAtezolizumab Plus Bevacizumab Versus Sorafenib in the Chinese Subpopulation With Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.hkuros316117-
dc.publisher.placeSwitzerland-
dc.identifier.issnl1664-5553-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats